Products
Innovative Therapies for Complex Diseases
Repligen's Development Pipeline
Repligen is developing a pipeline of innovative products and therapies with the potential to make a significant impact in the lives of patients suffering from diseases with limited treatment options. The company's diverse pipeline includes the following development programs:
- RG1068, synthetic human secretin, in Phase 3 development to improve magnetic resonance imaging of the pancreas
- RG2417, an oral formulation of uridine, in Phase 2b development for treatment of acute depression in bipolar disorder
- RG2833, HDAC-3 inhibitors in preclinical development for Friedreich's ataxia
- RG3039, promoters of SMN2 gene expression for spinal muscular atrophy
Whether addressing a large disease area such as bipolar disorder, or a smaller "orphan" patient population such as Friedreich's ataxia, Repligen's programs target novel biological pathways and have the potential to dramatically alter the course of disease.
For more information on a particular product candidate or indication, please click on the corresponding product name in the chart above.
A Trusted Supplier of Life Science Tools
Repligen's Bioprocessing Business
For over 20 years, Repligen's products have played a central role in the successful development and commercial production of biotherapeutic and diagnostic antibodies. Repligen's commitment to quality, depth of technical knowledge and track record for reliability make us the ideal partner to help meet the challenges facing the industry as it strives for biotherapeutic manufacturing industrialization. Repligen is leveraging its knowledge and expertise to provide new products that will enable more efficient, optimized and cost effective processes. Repligen's Bioprocessing division is estimated to record approximately $10.3 million of product revenue in fiscal year 2010 (ended March 31, 2010) and bioprocessing product revenues are currently forecast to increase 10-20% this next year.
Learn more about Repligen’s Bioprocessing Business.